Browse news and features about John Dawson, Chief Executive Officer of Oxford Biomedica – a leading gene and cell therapy group focused on developing life-changing treatments for serious diseases, based in Oxfordshire. The company was founded in 1995 as a spin-out from the Department of Biochemistry at the University of Oxford.
AstraZeneca has committed to an increase in the number of batches required from Oxford Biomedica in the second half of 2021.
The new 84,000 sq ft manufacturing facility based in Oxford was originally built to service the company’s growing demand for lentiviral vectors.
The Digital Scrip Awards took place on 02 December 2020 and acknowledged the outstanding achievements in pharmaceutical, biotech and other allied industries.
Oxford Biomedica and PhoreMost enter gene therapy discovery collaboration to develop next-generation CAR-T cell therapies with improved efficacy and durability.
Oxford Biomedica has announced MHRA approval for 4th GMP manufacturing suite within the Group’s new Oxbox manufacturing facility.
Oxford Biomedica has joined a consortium led by the Jenner Institute, Oxford University, to rapidly develop, scale-up and manufacture a potential vaccine candidate for COVID-19
Oxford Biomedica announces interim results to 30 June 2019 with revenues of £32.1m and operating EBITDA loss and operating loss of £1.4m and £6.1m respectively.
Oxford Biomedica receives £53.5m strategic investment from Novo Holdings in return for 6.56m new ordinary shares, 10.1% of the outstanding shares after the capital increase.
Oxford Biomedica announces preliminary results to 31 December 2018 with revenue up to £66.8 million and profit before tax of £5m compared to a loss in 2017.
Oxford Biomedica announces new digital framework initiative to streamline medicine production with £2m grant from Innovate UK, the UK’s innovation agency.